Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • jfk123_1 jfk123_1 Sep 29, 2013 8:37 PM Flag

    Looks like the bashers and their soft basher friends are hard at work

    Too bad the people who run this whole stock show don't post here or read this babble. And my posts don't matter either. I try to give honest information to retailers to try to help them make good decisions, but retailers do not call the shots, keep that in mind.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • whoa, whoa don't lose heart. I rarely if ever post but read everything and find your posts informative, insightful and spot on in regards to the science behind what's going on. I've been meaning to chat with you a bit, I was also seeing the ascending pennant (or at least that's what it looked like to me) and was intrigued with your posts when you mentioned the same finding. I do know (only because I have family members who are very experienced biologists) that fast track approval increases the likelyhood of FDA approval -its only given to drugs that show promis in treating life threatening conditions for which no other drug exists. Even if the drug were to turn out to have problems, ( and for the sake of cancer patients I hope not) it wouldn't be recalled from the market until around 12 mo. later. Then, all the lawyers would get involved and what they'd probably end up doing is just let the patients know that there were such and such side effects, for example Lipitor. So there is my small contribution to this discussion.

      • 1 Reply to joybug75
      • ""I do know (only because I have family members who are very experienced biologists) that fast track approval increases the likelyhood of FDA approval -its only given to drugs that show promis in treating life threatening conditions for which no other drug exists. ""

        Wrong. Fast track approval cuts the review time. The comment about you supposedly knowing very experienced biologists isn't relevant as it is about an FDA review process, not biology.

 
SNTA
2.09+0.02(+0.97%)Aug 4 4:00 PMEDT